Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.907675
Keywords
RVFV vaccine; adenovirus serotype 4 vector; glycoproteins; replication-competent; single-dose immunization; sterilizing protection
Categories
Funding
- National Natural Science Foundation of China
- Beijing Municipal Science and Technology Project
- [82101919]
- [Z201100005420024]
Ask authors/readers for more resources
Rift Valley fever virus (RVFV) is a severe pathogen with no approved vaccine for prevention. In this study, a new vaccine candidate, Ad4-GnGc, was developed and shown to induce strong immune responses in mice, protecting them from lethal infection. Importantly, Ad4-GnGc was effective even in the presence of pre-existing immunity to adenovirus serotype 5.
Rift Valley fever virus (RVFV) is one of the most important virulent pathogens causing severe disease in animals and humans. However, there is currently no approved vaccine to prevent RVFV infection in humans. The use of human adenovirus serotype 4 (Ad4) as a vector for an RVFV vaccine has not been reported. Here, we report the generation of a replication-competent recombinant Ad4 vector expressing codon-optimized forms of the RVFV glycoproteins Gn and Gc (named Ad4-GnGc). Intramuscular immunization with Ad4-GnGc elicited robust neutralizing antibodies against RVFV and cellular immune responses in mice. A single low-dose vaccination with Ad4-GnGc completely protected interferon-alpha/beta receptor-deficient A129 mice from lethal RVFV infection. More importantly, Ad4-GnGc efficacy was not affected by pre-existing immunity to adenovirus serotype 5, which currently exists widely in populations. These results suggest that Ad4-GnGc is a promising vaccine candidate against RVFV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available